A stronger debut just added to biotech’s improving IPO tone Odyssey Therapeutics opened at $20, above its $18 IPO price, in a debut that gave the Boston-based biotech an initial public valuation just under $900 million. That followed an upsized

What Happened Eli Lilly said it will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, giving the drugmaker a bigger foothold in next-generation cell therapy and cancer treatment. Lilly said it will pay $3.25 billion

What Happened UnitedHealth Group (UNH) and other major health insurers rallied on Tuesday after the Centers for Medicare & Medicaid Services, or CMS, said it would increase payments for Medicare Advantage plans next year. The agency said payments to insurers

From Europe’s Most Valuable Company to Market Reality Novo Nordisk’s meteoric rise during the Wegovy era has officially come full circle. Shares of the Danish drugmaker plunged more than 16%, wiping out the remaining gains tied to the explosive growth

Novo Nordisk Pushes Back on $49 Wegovy Alternative Novo Nordisk said Thursday it will pursue legal and regulatory action against Hims & Hers after the telehealth firm announced plans to sell a low-cost copy of Novo’s blockbuster Wegovy weight loss

What Was Said And Why It Matters During a cabinet meeting at the White House, the U.S. President said he spoke with the head of Eli Lilly (LLY) and was told the company is building six plants in the United States. The comments point to continued momentum behind

UnitedHealth Profit Outlook Beats — But Medicare Shock Dominates Shares of UnitedHealth Group fell after the insurer delivered a slightly better-than-expected 2026 profit forecast, overshadowed by a sharply disappointing proposal for Medicare Advantage reimbursement rates. The reaction highlights how sensitive

A $1 billion bet on AI-driven medicine AI chip leader Nvidia and pharmaceutical giant Eli Lilly announced a joint $1 billion investment to build a new artificial intelligence–focused drug discovery lab in San Francisco. The lab will be funded over

A New Push Toward Oral Weight-Loss Treatments AI meets metabolic medicine Nimbus Therapeutics announced a new research and licensing agreement with Eli Lilly to develop next-generation, AI-driven oral treatments for obesity and other metabolic diseases. Under the deal: The collaboration

Pfizer Lowers Earnings Outlook for 2026 Pfizer signaled continued pressure on its post-pandemic business, forecasting 2026 profit below analyst expectations as demand for COVID-related products continues to normalize. The drugmaker said it expects adjusted earnings of $2.80 to $3.00 per